← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #567 OF 1,000 MOST-CITED

Accurate reproduction

FDA cited this observation 32 times across 31 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs32
BY FISCAL YEAR
FY20253
FY20242
FY20234
FY20224
FY20212
FY20202
FY20193
FY20186
FY20176

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.4× the rate of the average FDA-cited firm (45.2% vs 8.3%), across 31 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

The batch production and control records are deficient in that they are not an accurate reproduction of the appropriate master production or control record.

Winder Laboratories, LLC · Winder, Georgia · Drugs · 2025-08-05

The batch production and control records are deficient in that they are not an accurate reproduction of the appropriate master production or control record.

Delicate Cosmetics, Inc. · Sun Valley, California · Drugs · 2025-06-27

The batch production and control records are deficient in that they are not an accurate reproduction of the appropriate master production or control record.

Quest Products LLC · Kent, Washington · Drugs · 2024-11-07

The batch production and control records are deficient in that they are not an accurate reproduction of the appropriate master production or control record and checked for accuracy, dated, and signed.

Aerosol and Liquid Packaging, Inc. · Baltimore, Maryland · Drugs · 2023-12-18

The batch production and control records are deficient in that they are not checked for accuracy, dated, and signed.

Landy International · Xia Men · Drugs · 2023-12-14

The batch production and control records are deficient in that they are not an accurate reproduction of the appropriate master production or control record.

Dercher Enterprises, Inc., DBA Gordon Laboratories · Upper Darby, Pennsylvania · Drugs · 2023-09-20

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →